Erasca, Inc. reported financial results for the fiscal quarter ended March 31, 2026.
“On May 11, 2026, Erasca, Inc. (the “Company”) announced the Company’s financial results for the three months ended March 31, 2026.”
Erasca, Inc. — fact timeline
Source-grounded facts extracted from Erasca, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Erasca, Inc. reported Q4 2025 results: net income -29.1 million, EPS -0.10.
“Net loss was $29.1 million, or $(0.10) per basic and diluted share, for the quarter ended December 31, 2025”
Erasca, Inc. announced a restructuring with charges of approximately $2.2 million affecting drug discovery functions or on the deprioritized programs (by approximately 18%).
“by approximately 18%, primarily affecting employees working in drug discovery functions or on the deprioritized programs. The Company anticipates recognizing approximately $2.2 million in total charges in the second quarter of 2024 in connection with the reduction in force. These charges will consist primarily of one-time cash charges for termination benefits.”
Erasca, Inc. entered into Medshine License Agreement with Medshine Discovery Inc. valued at $10.0 million (effective 2024-05-14).
“On May 14, 2024, the Company entered into an exclusive license agreement (the “Medshine License Agreement”) with Medshine Discovery Inc. (“Medshine”) under which the Company was granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Medshine to develop, manufacture and commercialize certain pan-KRAS inhibitors in all fields of use.”
Erasca, Inc. entered into Joyo License Agreement with Guangzhou Joyo Pharmatech Co., Ltd. valued at $12.5 million (effective 2024-05-14).
“On May 14, 2024, Erasca, Inc. (the “Company”) entered into an exclusive license agreement (the “Joyo License Agreement”) with Guangzhou Joyo Pharmatech Co., Ltd. (“Joyo”) under which the Company was granted an exclusive, worldwide (except mainland China, Hong Kong and Macau), royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Joyo to develop, manufacture, and commercialize certain pan-RAS inhibitors in all fields of use.”
Erasca, Inc. reported the fiscal quarter ended March 31, 2024 results: net income $35.0 million, EPS $(0.23) per basic and diluted share.
“Net loss was $35.0 million, or $(0.23) per basic and diluted share, for the quarter ended March 31, 2024”
Erasca, Inc. entered into Purchase Agreement with the purchasers named therein (the "Purchasers") valued at approximately $45 million (effective 2024-03-27).
“On March 27, 2024, Erasca, Inc. (the “Company”) entered into a stock purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of 21,844,660 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $2.06 per Share. The aggregate gross proceeds for the Private Placement are expected to be approximately $45 million, before deducting offering fees and expenses.”
Erasca, Inc. reported financial results for the fiscal quarter and full year ended December 31, 2023.
“On March 27, 2024, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Erasca, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $30.4 million, or $(0.20) per basic and diluted share, EPS $(0.20) per basic and diluted share.
“Erasca Reports Third Quarter 2023 Financial Results and Business Updates”
Erasca, Inc. reported quarter ended June 30, 2023 results: net income Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023, EPS $(0.21).
“Net loss was $31.8 million, or $(0.21) per basic and diluted share, for the quarter ended June 30, 2023”
Erasca, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-22 meeting.
“Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 For 122,279,001 Withheld 3,124 Against 32,293 There were 0 broker non-votes for this proposal. The appointment of KPMG LLP was ratified.”
Erasca, Inc. shareholders approved Election of three Class II Directors for a term of three years expiring at the 2026 annual meeting of stockholders at the 2023-06-22 meeting.
“Election of three Class II Directors for a term of three years expiring at the 2026 annual meeting of stockholders Alexander W. Casdin For 101,317,047 Withheld 8,205,892 Julie Hambleton, M.D. For 102,122,261 Withheld 7,400,678 Michael D. Varney, Ph.D. For 100,882,700 Withheld 8,640,239 There were 12,791,479 broker non-votes for this proposal. The three nominees for Class II Director were elected.”
Erasca, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 15, 2023, Erasca, Inc. announced its financial results for the quarter ended March 31, 2023.”
Shannon R. Morris was appointed as Chief Medical Officer at Erasca, Inc..
“Effective as of April 10, 2023, Shannon R. Morris, M.D., Ph.D. has been promoted to the position of the Chief Medical Officer of the Company.”
Wei Lin resigned as Chief Medical Officer at Erasca, Inc..
“On April 4, 2023, Wei Lin, M.D. notified Erasca, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company to pursue other opportunities.”
Erasca, Inc. reported financial results for the fiscal year ended December 31, 2022.
“On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
Erasca, Inc. reported financial results for the fourth quarter ended December 31, 2022.
“On March 23, 2023, Erasca, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
Erasca, Inc. entered into License Agreement with Novartis Pharma AG valued at $20 million upfront cash payment and approximately $80 million in shares (effective 2022-12-09).
“On December 9, 2022, Erasca, Inc. (the Company) entered into an exclusive license agreement (the License Agreement) with Novartis Pharma AG (Novartis) under which the Company was granted an exclusive, worldwide, royalty-bearing license to certain patent and other intellectual property rights owned or controlled by Novartis to develop, manufacture, use, and commercialize naporafenib in all fields of use.”
Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022.
“Erasca, Inc. announced its financial results for the quarter ended September 30, 2022.”
Jean Liu was appointed as Director at Erasca, Inc..
“the Board appointed Jean Liu, J.D., to fill such newly created directorship.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.